The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Broderick Dyer Preston - UBS Investment Bank, Research Division - Analyst
: Sorry I joined a little bit late. So if I repeat anything, just feel free to tell me to review the transcript. But I did think, John, I think I saw
you gave the shared national credit percentage at 12%. Do you happen to have, which you guys are the lead underwriter on, or the
agent on.
Question: Broderick Dyer Preston - UBS Investment Bank, Research Division - Analyst
: Okay. So less than 5% of the 12%.
Question: Broderick Dyer Preston - UBS Investment Bank, Research Division - Analyst
: Okay. Cool. And do you have a look on what the reserve on the office portfolio is at this point?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
OCTOBER 19, 2023 / 1:00PM, WBS.N - Q3 2023 Webster Financial Corp Earnings Call
Question: Broderick Dyer Preston - UBS Investment Bank, Research Division - Analyst
: Okay. Glenn, could you maybe speak around what the puts and the takes will be as it relates to NII and the NIM going forward?
Maybe help me better understand the cadence of fixed asset repricing throughout the fourth quarter and then through 2024 and
what the impact of the loan yields will be for that?
Question: Broderick Dyer Preston - UBS Investment Bank, Research Division - Analyst
: Got it. And then, John, I know you talked earlier about kind of the leverage loan and the sponsor specialty sponsor book. But I guess
I wanted to better understand kind of like some of the final points on the details of the underwriting there and kind of the things
you do to structure those loans to really give you protection.
And I'm not expecting you to speak to the specific credit. Like you all would underwrite it, credit, files for bankruptcy, but like the
ABL FILO notes in the market are trading at 92%, 93% of par. And so like market obviously expects very little loss. It looks like you
guys and the other banks in a position to kind of get paid back first. And it feels really well collateralized.
So could you just kind of help us better understand the structure of those deals and what you kind of do to help protect yourself in
the event that something goes wrong?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
OCTOBER 19, 2023 / 1:00PM, WBS.N - Q3 2023 Webster Financial Corp Earnings Call
Question: Broderick Dyer Preston - UBS Investment Bank, Research Division - Analyst
: Got it. And then the last one for me. I just wanted to ask around the HSA book. I feel like this has been a topic that's come up
sporadically over the last several years. But I wanted to ask just because other banks are looking to potentially monetize unique
assets that they have.
And so when I look at kind of what's happened in HSA, it feels like some of your nonbank competitors have been able to really kind
of pay really high multiples to acquire other HSA portfolios that otherwise -- I think if they had the same investor base that you do,
they wouldn't be able to pay as much.
And so with the growth in that business line kind of slowing to some extent and the value of it really not showing up in the multiple
and it being tough to kind of inorganically grow that business, just given that you're treated like a bank versus others that are treated
like nonbanks. Like how do you think about maybe monetizing that and doing something more strategic there to help your investors
realize the full value of that business?
| 
